Business context and reporting period
Merit Medical Systems, Inc. designs and sells medical devices used in interventional, diagnostic and therapeutic procedures. It reports two segments: cardiovascular and endoscopy. This is the fiscal-year 2022 Form 10-K for the year ended December 31, 2022; it does not provide standalone fourth-quarter results.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $1,151.0 million | $1,074.8 million |
| Gross profit / margin | $519.1 million / 45.1% | $485.3 million / 45.2% |
| Operating income | $87.6 million | $60.9 million |
| Net income | $74.5 million | $48.5 million |
| Diluted EPS | $1.29 | $0.84 |
| Cash from operating activities | $114.3 million | $147.2 million |
| Capital expenditures | $45.0 million | $27.9 million |
| Cash, cash equivalents and restricted cash at year-end | $60.6 million | $67.8 million |
| Long-term debt at year-end | $198.2 million | $242.8 million |
At year-end 2022, current assets were $529.1 million and current liabilities were $220.6 million. Operating lease liabilities totaled $70.7 million; contingent consideration liabilities totaled $18.1 million. The company reported approximately $523 million of additional borrowing availability under its credit agreement, subject to its leverage-based limit, and said it believed cash, operating cash flow and available borrowings would fund operations for at least the next 12 months.
Material changes versus the prior year
- Sales rose 7.1%, with U.S. sales up 6.8% and international sales up 7.4%. Management attributed growth to stronger-than-expected U.S. demand and improved international trends, especially in EMEA and the rest of the world.
- Cardiovascular sales increased 7.2% to $1,118.2 million; endoscopy sales increased 3.9% to $32.8 million. OEM grew 17.4%, peripheral intervention 8.6%, and cardiac intervention 7.0%; custom procedural solutions declined 1.9%.
- Operating income and net income improved substantially. The filing cites higher sales and lower legal settlement and impairment charges versus 2021, partly offset by labor, travel, freight and contingent consideration costs.
- Gross margin edged down to 45.1% from 45.2%, mainly due to less favorable manufacturing variances and higher freight costs, partly offset by product mix and other cost improvements.
- Operating cash flow declined $32.9 million, principally reflecting increased inventory investment, higher cash used for receivables and payment of the securities class-action settlement accrual. Inventory reached $266.0 million, up from $221.9 million.
- Debt declined from $242.8 million to $198.2 million. Variable-rate borrowings carried a 5.38% rate at year-end, compared with 1.10% on the comparable 2021 balance; $75 million was fixed at 2.71% through an interest-rate swap.
Outlook, risks, contingencies and unusual items
- Management forecast 2023 capital expenditures of approximately $55–$60 million. Its “Foundations for Growth” transformation program includes cost discipline and operational initiatives, with multi-year financial targets through 2023; specific target values are not provided in the supplied filing text.
- Management expected elevated inflation to continue in 2023. Risks include supply-chain and freight disruption, rising labor and input costs, pricing pressure, foreign-exchange movements, geopolitical and China-related uncertainty, and possible renewed COVID-19 disruption.
- Regulatory risks include EU Medical Device Regulation certification deadlines, possible product discontinuations or delayed launches, and the FDA approval process and clinical trial for the Wrapsody Endoprosthesis.
- The company remains subject to a five-year Corporate Integrity Agreement entered into in 2020. It also disclosed an SEC Enforcement Division inquiry seeking information about its China subsidiary’s dealings with hospitals and healthcare officials; Merit said it was cooperating and could not predict the scope, timing or outcome.
- A shareholder derivative action settlement required $1.0 million in attorneys’ fees and governance changes; the related expense was recorded in 2022 and court approval was announced in February 2023. The 2021 securities class-action settlement was paid in 2022, with insurance proceeds also collected.
- 2022 unusual charges included $6.7 million of acquired in-process R&D expense, $4.6 million of contingent consideration expense and $2.2 million of impairment charges. The company also recorded a $0.5 million impairment of its XableCath investment and a $1.7 million intangible-asset impairment associated with the STD Pharmaceutical divestiture.
- Deloitte issued unqualified opinions on the financial statements and internal control over financial reporting. Inventory valuation was identified as a critical audit matter, involving estimates of future demand and obsolete or slow-moving inventory.
Important facts for investors to verify
- Confirm the separate fourth-quarter 2022 results from the company’s quarterly filing or earnings release; this 10-K summarizes annual results.
- Track whether revenue growth and gross margins withstand inflation, freight costs, manufacturing variances and customer pricing pressure.
- Review inventory growth and operating cash flow conversion, including whether inventory levels normalize as planned.
- Monitor debt rates, covenant compliance, borrowing availability and the effect of higher interest costs.
- Follow the SEC inquiry, Corporate Integrity Agreement obligations, Wrapsody clinical and regulatory progress, and EU MDR certification or product-discontinuation decisions.
- Assess whether 2023 capital spending and the Foundations for Growth program deliver the expected operational and profitability benefits.